Dimethaid WF10 fails Phase III for HIV
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dimethaid is halting development of its HIV/AIDS agent WF10 following the immune regulator's failure to meet primary endpoints in a 96-week, placebo-controlled, double-blind Phase III trial. Results from the North American trial's 229 late-stage AIDS patients "indicated no statistical difference between WF10 and placebo in affecting the time to onset of clinical progression, defined as any new AIDS-defining event or death," the firm says July 14. Dimethaid plans to evaluate the study's secondary results and "re-evaluate WF10's future business potential and its position in the company's long-term development pipeline." The firm notes WF10 (tetrachlorodecaoxygen) may have potential in autoimmune diseases and oncology...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.